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The plasma membrane receptor for interleukin-1 (IL-l) has been characterized from mouse EL4-6.1 thymo- 
ma cells. Following binding of IL-l to surface labeled EL4-6.1 cells, the IL-l binding molecule was immuno- 
precipitated using a rabbit antiserum against the hormone. The putative IL- 1 receptor is a membrane-asso- 
ciated glycopeptide of A4, = 82000 containing probably two or three N-linked glycan units as indicated by 
its conversion into a M,= 60000 polypeptide upon deglycosylation with endo-/?-?%glycosidase F. 
Interleukin-1 receptor; Recombinant interleukin-1; (Mouse EL4-6.1 cell) 
1. INTRODUCTION 
Interleukin 1 (IL-l) is a family of at least 2 
polypeptide hormones released by macrophages 
which act as major mediators of inflammatory 
responses [l-4]. IL-l biological activity is mediat- 
ed via binding to specific cell surface receptor(s), 
the functional properties of which have recently 
been reviewed [5]. Although IL-1 binding sites 
have been identified on a variety of cell types [4,5], 
the low number of receptors observed even on 
highly IL-l-responsive cell lines and the lack of 
specific anti-receptor antibodies so far has ham- 
pered detailed structural studies. However, an 
IL-l-binding membrane polypeptide was identified 
on both murine and human cells by treatment of 
surface-bound radioiodinated 12’I-IL-l with bi- 
valent water-soluble cross-linkers [6-g]. 
Recently, we have described a mutant subclone 
of the EL-4 mouse thymoma (EL4-6.1) [lo] that 
expresses an unusually high number of IL-l 
binding sites (-20.000 per cell) [l I], thus repre- 
senting a suitable model for further biochemical 
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studies. In this report, we have used this cell line in 
conjunction with recombinant IL-l (rIL-1) [12] 
and a rabbit antiserum to the hormone in order to 
identify and partially characterize the plasma 
membrane-associated rIL-l-binding protein. 
2. MATERIALS AND METHODS 
2.1. Cell cultures 
The murine T cell lines used in this study were 
the EL4 thymoma sublines EL4-6.1 [lo] and EL4-3 
(an independent non-IL-2 secreting subline). Cells 
were cultured in enriched DME and maintained at 
37°C in a humidified atmosphere of 5% CO2 in 
air. 
2.2. Reagents 
The CY form of purified human recombinant 
interleukin-1 (rIL-la) [13] and hyperimmune rab- 
bit antiserum anti-rIL-la were provided by Biogen 
SA, Geneva, Switzerland. One microgram of the 
IgG fraction of this antiserum completely inhibited 
the binding of 1251-rIL-lcu to EL4-6.1 cells whereas 
50% inhibition was obtained with 0.1 pug/ml (not 
shown). 
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2.3. Cell labeling and rIL-lcu binding 
Cells were labeled by the enzyme-catalysed sur- 
face iodination [14] with previously described 
modification [ 151. After labeling, 10 x lo6 cells 
were incubated for 4 h at 4°C with or without 1 
pg/ml of rIL-la in 1 ml of DME with 20% fetal 
calf serum (FCS). This represented approximately 
ten times the saturating concentration for low af- 
finity IL-l receptor [I 11. Cells were then washed 
five times with cold PBS and lysed in 25 mM Tris- 
HCl, pH 8.4, buffer supplemented with 0.5% 
Nonidet-P40 (NP-40), 0.5% sodium deoxycholate 
(DOC), 50 mM NaCl, 0.01% NaNs, 2 mM PMSF 
and lOpg/ml of leupeptin, pepstatin and antipain 
(Sigma, St. Louis, MO). Alternatively, the incuba- 
tion with 1 pg/ml of rIL-la was performed after 
lysis of labeled cells for 4 h at 4°C followed by 
overnight dialysis in the cold. 
2.4. Immunoprecipitation 
The lysates of 15-20 x lo6 cells were precleared 
with 10~1 of normal rabbit serum followed by 50 
,J of protein A-coupled to Sepharose 4B (Phar- 
macia, Uppsala). The cleared lysates were filtered 
through.0.2 pm Millipore filters before addition of 
2O,J(- 1OOpg of protein A binding IgG) of rabbit 
anti-rIL-lcu antiserum. After 45 min of incubation 
at room temperature, 50 ~1 of protein A-Sepharose 
were added and incubation prolonged for 30 min. 
Immunoprecipitates were washed 3 times in 10 mM 
phosphate buffer at pH 8.2 supplemented with 
0.05% SDS, 0.05% DOC, 0.5% NP-40, 10 mM 
EDTA and alternatively 3 times with 120 mM Tris- 
HCI buffer at pH 8.2 containing 100 mM NaCI, 
0.5% NP-40 and 10 mM EDTA. 
2.5. Enzyme digestions 
Digestions of immunoprecipitates with endo-,&- 
N-acetylglucosaminidase H (endo-H) were per- 
formed as previously described [ 151. In brief, im- 
munoprecipitates were heated with 0.1 M Tris-HCl 
buffer, pH 7.5, 1% SDS, and 1% 2-fl-mercapto- 
ethanol for 5 min. This solution was diluted with 
9 vols of 0.15 M sodium citrate buffer, pH 5.5, 
containing 4 mM PMSF, 10 pg/ml of pepstatin, 
leupeptin and antipain, and 3 mIU of endo-H 
(New England Nuclear, Boston, MA) and was in- 
cubated at 37°C for 16 h. Proteins were recovered 
by precipitation with an equal volume of 30% 
(w/v) trichloroacetic acid. The sediment was wash- 
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ed twice with ice-cold acetone. Digestions with 
endo-P-N-acetylglucosaminidase F (endo-F) were 
carried as follows: the immunoprecipitates were 
solubilized as for endo-H digestion and then 
diluted nine times with 0.1 M sodium phosphate 
buffer, pH 6.1, containing 50 mM EDTA. 1% 
NP-40, 1% 2-,&-mercaptoethanol, 4 mM PMSF, 
and lO~g/ml of pepstatin, leupeptin and antipain, 
0.4 U of endo-F preparation (New England Nu- 
clear, Boston, MA) were then added. The mixture 
was incubated at 37°C overnight. Proteins were 
recovered as described for endo-H digestion. 
2.6. Polyacrylamide gel electrophoresis 
One-dimensional polyacrylamide gel electro- 
phoresis in SDS (SDS-PAGE) was carried out on 
10% or lo-13% gradient gels according to Laem- 
mli [ 161. Immunoprecipitates were dissolved in 80 
mM Tris-HCl buffer, pH 6.8, 0.1 M dithiothreitol, 
4% SDS, 10% glycerol, and 0.01% bromphenol 
blue (sample buffer) at 100°C for 5 min before 
layering onto the gel. The following molecular 
mass standards (in Da) were used: P-galactosidase 
(116 000), phosphorylase b (94 000), transferrin 
(78 000), bovine serum albumin (69000), oval- 
bumin (46 000), glyceraldehyde-3-P-dehydrogen- 
ase (34 000), cu-chymotrypsinogen (25 000) and 
cytochrome c (12 500). 
3. RESULTS AND DISCUSSION 
In view of the slow dissociation rate of IL-l 
from its receptor on intact cells (tl,+4 h) [6,1 I], 
we decided to immunoprecipitate the putative 
plasma membrane receptor for IL-l from surface 
iodinated EL4-6.1 cell lysates previously incubated 
with rIL-la (see section 2, using a rabbit antiserum 
against human rIL-la. Thus a single labeled 
polypeptide of an apparent molecular mass of 
80-85 kDa under both reducing and non reducing 
conditions could be specifically immunopurified 
after preincubation of the labeled cells with rIL-la 
(fig.lA, lane 1). This component was not detected 
when the incubation of the cells with rIL-lcu was 
omitted prior to immunoprecipitation (fig. 1 A, 
lane 2). In addition, it was not found when rIL-la 
was added to EL4-3 cells, a thymoma line recently 
shown to be negative for the expression of the IL-l 
receptor [ll] (fig.lB, lanes 3-4). Moreover, the 
polypeptide partitioned into the detergent phase of 
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Fig. I. (A) Autoradiograph of 10% SDS-PAGE under reductive conditions. Immunoprecipitates with rabbit anti-rIL-lcr 
of surface-labeled EL4-6.1 cells incubated with (+) or without (-) rIL-lcu (lanes 1,2). Lane 3: preclearing with normal 
rabbit serum. (B) Autoradiographs of 10% SDS-PAGE under non-reductive conditions. Immunoprecipitates with 
rabbit anti-rIL-1cY of surface-labeled cells incubated with (+) or without (-) rIL-lcu. Lanes 1,2: EL4-6.1 cells; lanes 
3,4: EL4-3 cells. (C) Autoradiographs of 10% SDS-PAGE under reductive conditions. Immunoprecipitates with rabbit 
anti-rIL-lcu. Lane 1: surface labeled cells incubated with rIL-lc and extracted with TX-114 prior to 
immunoprecipitation; lanes 2,3: surface labeled cells extracted with NP 4O/DOC. Lysates were incubated with (+) or 
without (-) rIL-lcr prior to immunoprecipitation. 
Triton X-114 which is suggestive for the existence 
of a hydrophobic detergent-binding domain of the 
protein [17] (fig.lC, lane 1). 
The same 80-85 kDa polypeptide could also be 
immunopurified when rIL-la was incubated with 
cell lysates, thus indicating that the interaction of 
IL-la with its putative surface-expressed receptor 
also occurs after detergent extraction of membrane 
proteins (fig. lC, lanes 2,3). 
In some experiments two surface-labeled poly- 
peptides of apparent molecular mass of 45-50 and 
29-30 kDa, respectively, co-precipitated with the 
80-85 kDa component. Their possible relationship 
to the IL-l receptor cannot be excluded. However, 
they represented ~5% of the total immunopre- 
cipitated radioactivity. Moreover, the 45-50 kDa 
polypeptide also found in the absence of IL-la was 
a major component of the preclearing step (fig. 1 A, 
lane 3). It is therefore likely that it represented a 
contaminant of the specific immunoprecipitates. 
Digestion of the immunopurified putative IL-l 
receptor with endo-,&V-glycosidase F generated a 
band of apparent molecular mass of 60 kDa 
(fig.2A). In contrast, treatment with endo-&N- 
glycosidase H had no effect (fig.2B). In addition, 
a minor polypeptide of -30 kDa was generated 
upon endo-F treatment (fig.%A). This probably 
represented the deglycosylated form of the 45-50 
kDa contaminant described above. 
These preliminary structural studies indicate 
that the 80-85 kDa polypeptide is glycosylated and 
the shift in apparent molecular mass observed is 
consistent with the presence of two or three N- 
linked glycan units of the endo-H-resistant (i.e. 
complex) type. 
In conclusion, these data represent the first 
direct identification of the plasma membrane com- 
ponent reacting specifically with IL-la. In addi- 
tion, they confirm and extend the preliminary 
biochemical characterization of the putative IL-l 
367 
Volume 219, number 2 FEBS LETTERS July 1987 
Fig.2. Autoradiographs of IO-13% SDS-PAGE under 
reductive conditions. Immunoprecipitates with rabbit 
anti-rIL-lcu of surface labeled EL4-6.1 cells incubated 
with rIL-lcu. (A) Digestion with endo-F (lane 1) and 
control (lane 2). (B) Digestion with endo-H (lane 1) and 
control (lane 2). 
receptor detected by chemically cross-linking 
radioactive IL-l to the cell surface [6-91. 
ACKNOWLEDGEMENTS 
The rIL- and the rabbit antiserum to the hor- 
mone were kindly provided by Biogen S.A. (Gene- 
va, Switzerland). We wish to thank Mrs M.-C. 
Knecht for excellent secretarial assistance and Mr 
Z. Freiwald for photographical work. This work 
was supported in part by Grant 3.385-0.86 from 
the Swiss National Foundation for Scientific 
Research to C.B. 
REFERENCES 
[II 
PI 
[31 
[41 
151 
@I 
[71 
181 
191 
[lOI 
[Ill 
[I21 
[I31 
1141 
[I51 
[I61 
1171 
Mizel, S.B. (1982) Immunol. Rev. 63, 51-72. 
Smith, K.A., Lachman, L.B., Oppenheim, J. J. and 
Favata, M.F. (1980) J. Exp. Med. 151, 1551-1556.’ 
Oppenheim, J.J. and Gery, I. (1982) Immunol. 
Today 3, 113-119. 
Oppenheim, J.J., Kovacs, E.J., Matsushima, K. 
and Durum, S.K. (1986) Immunol. Today 7,45-56. 
Dower, S.K. and Urdal, D.L. (1987) Immunol. 
Today 8, 46-51. 
Dower, S.K., Kronheim, S.R., March, C.J., 
Conlon, P.J., Hopp, T.P., Gilles, S. and Urdal, 
D.L. (1985) J. Exp. Med. 162, 501-515. 
Matsushima, K., Akahoshi, T., Yamada, M., 
Furutani, Y. and Oppenheim, J.J. (1986) J. 
Immunol. 136, 4496-4502. 
Dower, S.K., Call, S.M., Gilles, S. and Urdal, 
D.L. (1986) Proc. Natl. Acad. Sci. USA 83, 
1060-1064. 
Chin, J., Cameron, P.M., Rupp, E. and Schmid, 
J.A. (1987) J. Exp. Med. 165, 70-86. 
Zubler, R.H., Erard, F., Lees, R.K., Van Laer, 
M., Mingari, C., Moretta, L. and MacDonald, 
H.R. (1985) J. Immunol. 134, 3662-3668. 
Lowenthal, J.W. and MacDonald, H.R. (1986) J. 
Exp. Med. 164, 1060-1074. 
MacDonald, H.R., Wingfield, P., Schmeissner, 
U., Clore, G. and Gronenborn, A.M. (1986) FEBS 
Lett. 209, 295-298. 
March, C.J., Mosley, B., Larsen, A., Ceretti, 
D.P., Braedt, G., Price, V., Gillis, S., Henney, 
C.S., Kronheim, S.R., Grobstein, K., Conlon, 
P.J., Hopp, T.P. and Cosman, D. (1986) Nature 
315, 641-647. 
Hubbard, A.L. and Cohn, Z.A. (1985) J. Cell Biol. 
64, 438-460. 
Luescher, B.H., Naim, H.R., MacDonald, H.R. 
and Bron, C. (1984) Mol. Immunol. 21, 329-336. 
Laemmli, U.K. (1970) Nature 227, 680-685. 
Bordier, C. (1981) J. Biol. Chem. 256, 1604-1607. 
368 
